Gracell

News

ASH: AstraZeneca's dual-wielding CAR-T shows promise

AstraZeneca has reported an impressive 96% response rate in the DURGA-1 of BCMAxCD19 CAR-T therapy AZD0120 in heavily pretreated multiple myeloma.

News

AZ makes another cell therapy play with $1.2bn Gracell buy

AstraZeneca has lined up a $1.2 billion takeover deal for Chinese biotech Gracell Biotechnologies, bolting a series of cell therapies for cancer and autoimmune diseases on

News

Flagship joins three biotechs together to form Etcelera

Flagship Pioneering has formed a new AI-focused biotech company, called Etcelera, by combining the platforms of three firms from its portfolio.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Digital

Discover a new era of healthcare panel engagement: Grounded ...

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.

Editor's Picks